Skip to main content

Efalizumab Pregnancy and Breastfeeding Warnings

Brand names: Raptiva

Efalizumab Pregnancy Warnings

Efalizumab has been assigned to pregnancy category C by the FDA. Animal studies have not been performed. There are no controlled data in human pregnancy. Efalizumab should only be given during pregnancy when need has been clearly established.

Healthcare providers are encouraged to enroll patients who become pregnant while taking efalizumab (or within six weeks of discontinuing the drug) in the Raptiva pregnancy registry.

See references

Efalizumab Breastfeeding Warnings

There are no data on the excretion of efalizumab into human milk. Because maternal immunoglobulins are known to be present in the milk of lactating mothers, and animal data suggest the potential for adverse effects from efalizumab in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Multum Information Services, Inc. Expert Review Panel"
  2. (2003) "Product Information. Raptiva (efalizumab)." Genentech

References for breastfeeding information

  1. (2003) "Product Information. Raptiva (efalizumab)." Genentech

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer